Novartis Pushes Up Nilotinib Filing Plans To Late 2006
The firm will position the tyrosine kinase inhibitor as a treatment for Gleevec-resistant or –intolerant patients.
The firm will position the tyrosine kinase inhibitor as a treatment for Gleevec-resistant or –intolerant patients.